The stock had advanced 2.44% in the past two sessions to end at Rs 415.50 yesterday, from its recent closing low of Rs 405.60 recorded on 10 July 2023.

On a year-to-date (YTD) basis, the stock has lost 21.58% while the benchmark Sensex has added 7.99% during the same period.

On the technical front, the stock's daily RSI (relative strength index) stood at 44.212. The RSI oscillates between zero and 100. Traditionally, the RSI is considered overbought when above 70 and oversold when below 30.

On daily chart, the stock is trading below its 50-day, 100-day and 200-day simple moving average (SMA) placed at 417.98, 416.16and 469.91, respectively.

Jubilant Ingrevia said that it has issued commercial papers (CPs) of Rs 100 crore on 12 July 2023.

The tenure of the said instrument is 44 days and coupon rate is 7.15% per annum.

The repayment of the same will be done on 25 August 2023.

The finance committee of the company, at its meeting held on 06 February 2021, had approved issuance of commercial papers up to an amount of Rs 450 crore outstanding at any point of time, in one or more tranches.

"The aggregate amount of commercial papers (including this issue) outstanding as on date is Rs 200 crore,” Jubilant Ingrevia said in a statement.

Jubilant Ingrevia is a global integrated life science products and innovative solutions provider serving, pharmaceutical, nutrition, agrochemical, consumer and industrial customers with its customised products and solutions that are innovative, cost effective and conforming to premium quality standards. The company is engaged in manufacturing and supply of speciality chemicals, nutrition & health solutions and chemical intermediates through five manufacturing facilities in India.

The company had reported 23.74% decline in consolidated net profit to Rs 52.31 crore on a 11.47% fall in sales to Rs 1129.48 crore in Q4 FY23 over Q4 FY22.